Satavaptan (sr121463) (DrugBank: Satavaptan)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
72 | Pituitary ADH secretion disorder | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00728091 (ClinicalTrials.gov) | July 2008 | 31/7/2008 | A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia | A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) | Hyponatremia;Inappropriate ADH Syndrome | Drug: satavaptan (SR121463);Drug: placebo | Sanofi | NULL | Terminated | 18 Years | N/A | Both | 2 | Phase 3 | United States |